[1] |
Hook EW Rd. Syphilis[J]. Lancet, 2017, 389(10078): 1550⁃1557. DOI: 10.1016/S0140⁃6736(16)32411⁃4.
|
[2] |
World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections: 2008. World Health Organization[J]. Reproductive Health Matters, 2012, 20(40): 207⁃209.
|
[3] |
中国国家卫生计生委疾病预防控制局. 2016年全国法定传染病疫情概况[DB/OL]. [2017⁃02⁃25]. http://www.nhfpc.gov.cn/jkj/s3578/201702/38ca5990f8a54ddf9ca6308fec406157. shtml.
|
[4] |
Seña AC, Wolff M, Behets F, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin[J]. Clin Infect Dis, 2013, 56(3): 420⁃422. DOI: 10.1093/cid/cis918.
|
[5] |
Zhou P, Gu X, Lu H, et al. Re⁃evaluation of serological criteria for early syphilis treatment efficacy: progression to neurosyphilis despite therapy[J]. Sex Transm Infect, 2012, 88(5): 342⁃345. DOI: 10.1136/sextrans⁃2011⁃050247.
|
[6] |
Shi M, Peng RR, Gao Z, et al. Risk profiles of neurosyphilis in HIV⁃negative patients with primary, secondary and latent syphilis: implications for clinical intervention[J]. J Eur Acad Dermatol Venereol, 2016, 30(4): 659⁃666. DOI: 10.1111/jdv.13514.
|
[7] |
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015[J]. MMWR Recomm Rep, 2015, 64(3): 34⁃48.
|
[8] |
Ghanem KG, Moore RD, Rompalo AM, et al. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV⁃infected patients[J]. Clin Infect Dis, 2008, 47(2): 258⁃265. DOI: 10.1086/589295.
|
[9] |
Jinno S, Anker B, Kaur P, et al. Predictors of serological failure after treatment in HIV⁃infected patients with early syphilis in the emerging era of universal antiretroviral therapy use[J]. BMC Infect Dis, 2013, 13: 605. DOI: 10.1186/1471⁃2334⁃13⁃605.
|
[10] |
Tittes J, Aichelburg MC, Antoniewicz L, et al. Enhanced therapy for primary and secondary syphilis: a longitudinal retrospective analysis of cure rates and associated factors[J]. Int J STD AIDS, 2013, 24(9): 703⁃711. DOI: 10.1177/0956462413480721.
|
[11] |
Wu BR, Tsai MS, Yang CJ, et al. Spirochetemia due to Treponema pallidum using polymerase⁃chain⁃reaction assays in patients with early syphilis: prevalence, associated factors and treatment response[J]. Clin Microbiol Infect, 2014, 20(8): O524⁃527. DOI: 10.1111/1469⁃0691.12504.
|
[12] |
Fiumara NJ. Serologic responses to treatment of 128 patients with late latent syphilis[J]. Sex Transm Dis, 1979, 6(4): 243⁃246.
|
[13] |
Romanowski B, Sutherland R, Fick GH, et al. Serologic response to treatment of infectious syphilis [J]. Ann Intern Med, 1991, 114(12): 1005⁃1009.
|
[14] |
Fiumara NJ. Treatment of primary and secondary syphilis: serologic response[J]. J Am Acad Dermatol, 1986, 14(3): 487⁃491.
|
[15] |
Peng RR, Wu J, Zhao W, et al. Neutropenia induced by high⁃dose intravenous benzylpenicillin in treating neurosyphilis: does it really matter?[J]. PLoS Negl Trop Dis, 2017, 11(3): e0005456. DOI: 10.1371/journal.pntd.0005456.
|
[16] |
中国中西医结合学会皮肤性病专业委员会性病学组. 梅毒血清固定临床处理专家共识[J]. 中华皮肤科杂志, 2015, 48(11): 753⁃755. DOI: 10.3760/cma.j.issn.0412⁃4030.2015.11.001.
|
[17] |
周平玉. 对成人早期梅毒治疗方案及治疗后评估的思考[J]. 中华皮肤科杂志, 2009, 42(5): 679⁃682.
|
[18] |
Seña AC, Zhang XH, Li T, et al. A systematic review of syphilis serological treatment outcomes in HIV⁃infected and HIV⁃uninfected persons: rethinking the significance of serological non⁃responsiveness and the serofast state after therapy[J]. BMC Infect Dis, 2015, 15: 479. DOI: 10.1186/s12879⁃015⁃1209⁃0.
|